Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04824092 · ClinicalTrials.gov registry record · Phase 3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
A Phase 3 study of Diffuse Large B Cell Lymphoma, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 899
- Enrollment target
- 20
- Study locations
NCT04824092: Active Phase 3 study of Diffuse Large B Cell Lymphoma, sponsored by Incyte Corporation.
NCT04824092 is a Phase 3 study of Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 899 participants, above the 211-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (326% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04824092, a Phase 3 study of Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 899 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL
Primary Outcome
Progression-Free Survival as assessed by the investigator using the Lugano Response Criteria for Malignant Lymphoma
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Tafasitamab
Study Locations (20)
California
- MorphoSys Research Site - Anaheim
- MorphoSys Research Site - Clovis
- MorphoSys Research Site - Fullerton
- MorphoSys Research Site - Harbor City
- MorphoSys Research Site - Los Angeles
- MorphoSys Research Site - San Diego
- MorphoSys Research Site - Whittier
Maryland
- MorphoSys Research Site - Baltimore
- MorphoSys Research Site - Bethesda
- MorphoSys Research Site - Columbia
Kentucky
- MorphoSys Research Site - Lexington
- MorphoSys Research Site - Louisville
Minnesota
- MorphoSys Research Site - Minneapolis
- MorphoSys Research Site - Rochester
Alabama
- MorphoSys Research Site - Daphne
Colorado
- MorphoSys Research Site - Aurora
Florida
- MorphoSys Research Site - Jacksonville
Hawaii
- MorphoSys Research Site - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 899 participants |
| Start Date | 2021-05-11 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 3 |
What the registry record for NCT04824092 still lists
NCT04824092 is an interventional study that assigns participants to a tested intervention. The registered 899 participants enrollment target is mid-sized for trials with a published cap, above the 211-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (326% higher).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04824092 names 20 study sites across 10 states, led by California, Maryland, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04824092 about?
NCT04824092 is a clinical study titled "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients". This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) ve...
What is the current status of trial NCT04824092?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 899 participants. The study started on 2021-05-11. Estimated completion is 2027-11-01.
What conditions does trial NCT04824092 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT04824092?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Rituximab (DRUG), Lenalidomide (DRUG), Tafasitamab (DRUG).
Who is sponsoring clinical trial NCT04824092?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04824092 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04824092's enrollment target sits among peer trials
899 6th of 114 higher than 109 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
RECRUITING · Phase 3
-
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RECRUITING · Phase 3
-
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI